Human Amnion Epithelial Cell Therapy for Chronic Liver Disease

Neil Andrewartha, George Yeoh

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)


Liver fibrosis is a common consequence of chronic liver disease. Over time, liver fibrosis can develop into liver cirrhosis. Current therapies for liver fibrosis are limited, and liver transplant is the only curative therapy for patients who progress to end-stage disease. A potential approach to treat chronic liver disease with increasing interest is cell-based therapy. Among the multiple cell types which have been proposed for therapeutic uses, human amnion epithelial cells and amniotic fluid-derived mesenchymal cells are promising. These cells are highly abundant, and their use poses no ethical concern. Furthermore, they exert potent anti-inflammatory and antifibrotic effects in animal models of liver injury. This review highlights the therapeutic characteristics and discusses how human amnion epithelial cells can be utilised as a therapeutic tool for chronic liver disease.

Original languageEnglish
Article number8106482
Number of pages10
JournalStem Cells International
Publication statusPublished - 7 Aug 2019


Dive into the research topics of 'Human Amnion Epithelial Cell Therapy for Chronic Liver Disease'. Together they form a unique fingerprint.

Cite this